Testing gene changes in PV or ET and blood clot risk
Treatments studied
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You were diagnosed with PV or ET recently—at diagnosis or within 1 year
- You have the JAK2 V617F gene mutation
- You have not started blood-count–lowering (cytoreductive) treatment yet when your blood is drawn
- You can give written consent and agree to join the FIMBANK registry (extra consent form)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain markers in the blood to see if they can predict blood clots in people with myeloproliferative neoplasms (MPN) like polycythemia vera, essential thrombocythemia, or pre-myelofibrosis. It is only for people who have a specific JAK2 mutation and are at high risk for clots, and who are already enrolled in another trial and a biobank.
This study looks at immune cells (monocytes) in people with certain blood cancers. Researchers want to understand how these cells behave and change over time. You can join if you are newly diagnosed and haven't started treatment yet.
This study looks for factors that may predict how well people with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis respond to first treatments such as hydroxyurea or pegylated interferon. It may help doctors choose better treatments by learning what differences affect outcomes.
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.